ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
DermTech Inc

DermTech Inc (DMTK)

0.094
0.00
(0.00%)
Closed July 12 4:00PM
0.094
0.00
( 0.00% )
Pre Market: 8:00PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.094
Bid
0.093
Ask
0.0931
Volume
-
0.00 Day's Range 0.00
0.0875 52 Week Range 3.8984
Previous Close
0.094
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
2,267,644
Financial Volume
-
VWAP
-

DMTK Latest News

DermTech Files for Voluntary Chapter 11 Protection

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in...

DermTech Reports First-Quarter 2024 Financial Results

- Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 7 percent versus the first quarter of 2023 DermTech, Inc. (NASDAQ:...

DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its...

DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effective March 27, 2024...

DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
4-0.216-69.67741935480.310.3480.0875108647640.11823244CS
12-0.5316-84.97442455240.62560.6750.087522676440.19939649CS
26-1.346-93.47222222221.441.440.087511047500.319773CS
52-3.166-97.11656441723.263.89840.08757146400.71433507CS
156-34.186-99.725787631334.2839.450.08756518797.31193426CS
260-5.386-98.28467153285.4884.490.087557860118.16991553CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DJTTrump Media and Technology Group Corporation
$ 53.80
(74.17%)
1.11M
PHUNPhunware Inc
$ 9.10
(56.09%)
234.11k
INTZIntrusion Inc
$ 1.74
(45.00%)
266
CPOPPop Culture Group Company Ltd
$ 1.86
(44.19%)
127.38k
DATSDatChat Inc
$ 1.39
(33.65%)
77.07k
EASTEastside Distilling Inc
$ 1.00
(-16.67%)
14.82k
QLGNQualigen Therapeutics Inc
$ 0.365
(-15.92%)
314.53k
IVPInspire Veterinary Partners Inc
$ 9.00
(-14.85%)
11.58k
KZIAKazia Therapeutics Ltd
$ 0.7796
(-12.97%)
89.21k
VEVVicinity Motor Corporation
$ 0.63
(-11.65%)
44.85k
MAXNMaxeon Solar Technologies Ltd
$ 0.2209
(-6.99%)
1.17M
DJTTrump Media and Technology Group Corporation
$ 53.79
(74.13%)
1.12M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 15.48
(10.41%)
366.95k
QLGNQualigen Therapeutics Inc
$ 0.365
(-15.92%)
314.77k
PHUNPhunware Inc
$ 9.13
(56.60%)
234.46k

DMTK Discussion

View Posts
Awl416 Awl416 4 weeks ago
DermTech Files for Voluntary Chapter 11 Protection
👍️0
Termite7 Termite7 2 months ago
Has possibilities.....
👍️0
Zardiw Zardiw 2 months ago
$DMTK Book Value: $1.65, Trading at .30 ......1/5 Book Value...............Z
👍️0
Monksdream Monksdream 4 months ago
DMTK new 52 week low
👍️0
Monksdream Monksdream 4 months ago
DMTK new 52 week low
👍️0
Monksdream Monksdream 4 months ago
DMTK new 52 week low
👍️0
Awl416 Awl416 6 months ago
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types
👍️0
makinezmoney makinezmoney 2 years ago
$DMTK: As long as the outcome is In cum

Its all good.

Hope you have MONSTER CAPITAL Gain issues in 2023 and end up paying back
$350Milly back to Uncle Sam.

I wish you no other problems.... other than this one


GO $DMTK
👍️0
reena969 reena969 2 years ago
Not too much $$$, I'm just looking for a new strategy for 2023. More in the line of the AVYA, JZ and GSUN plays I made. This girl is going BOTTOM DIGGING this year. Creating a new scanner as I type this. Guess I'm going to be that BOTTOM B*!%#...lol
👍️0
makinezmoney makinezmoney 2 years ago
$DMTK:: AWwwwwwwwwwwwwww you poooorrrrrr thanggggggggg


YOu made too much money.


Awwwwwwwwwww.............. that soooooooooo.


Whats the word I'm looking for .... ummmmmmmmm


FUCKING AMAZING !!!!!!!!!!



GO $DMTK
👍️0
reena969 reena969 2 years ago
I'm taking it EZ my capital gain Tax for 2023 are already in excessive of what I expected for the first quarter of 2023. I'm going to be doing some long term swings for awhile. December I was makin money too EZ...lol,lol.
👍️0
makinezmoney makinezmoney 2 years ago
$DMTK: Hey you..... you watching me...............

Across a crowded room ????


Rrrrawwwwwwwwwrrrrrrrrrrrrrr


Ya, I see a bunch right now.......... lots of action these past two weeks.


GO $DMTK
👍️0
reena969 reena969 2 years ago
Hey you...keep an eye on my previous post. Something may come of it. Maybe a nice swing trade for you, oops, sorry I forgot you like to scalp...lol
👍️0
makinezmoney makinezmoney 2 years ago
$DMTK: Boosting now.......... 2.65


Look at her ripppppppppppppppppppppppppppppppppp


Boommmm

GO $DMTK
👍️0
andypro andypro 3 years ago
Docs don't like it as it eliminates fast easy skin biopsy but patient demand will propel this!

Reply
👍️0
slow_feet slow_feet 4 years ago
Long straddle on this today.
👍️0
jaj-dan jaj-dan 4 years ago
Y’all just got a mention on FOXBusiness radio.
👍️0
The Lawman The Lawman 4 years ago
What other company has non-invasive band-aid type skin biopsies that are far more accurate than those performed with a scalpel?
👍️0
greens12 greens12 4 years ago
Strong day today , still very undervalued compared to EXAS. I have a 20.00 target by EOY and next year 80.00 +. GLTA

DMTK
👍️0
JB-22 JB-22 4 years ago
Thanks. I appreciate it. I confirmed with CFO. Have a great day.
👍️0
greens12 greens12 4 years ago
Hey JB, You might want to call and check but last i heard was Four warrants to buy 1 share at $23 with an expiration date 8/29/2024.

DMTK


👍️0
JB-22 JB-22 4 years ago
What’s the strike price on the DMTKW warrants? I know they expire 2024 but can find a strike?
👍️0
greens12 greens12 4 years ago
High negative predictive value of >99% suggests role for DermTech PLA as a non-invasive rule-out tool for melanoma

LA JOLLA, Calif.--(BUSINESS WIRE)--May 20, 2020-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the DermTech Pigmented Lesion Assay (the “DermTech PLA”) is reviewed in the Journal of the American Academy of Dermatology (“JAAD”) by leading dermatologists at the New York University School of Medicine as one of four novel molecular technologies with the potential to address current gaps in melanoma management through improved diagnostic accuracy and prognostication. Since its launch in 2016, the DermTech PLA, DermTech’s non-invasive adhesive patch test for melanoma detection, has been used to assess more than 50,000 lesions and remains the first and only non-invasive gene expression test in dermatology, providing objective genomic data to help guide clinical decisions.

The article published in JAAD summarizes a review of four molecular technologies that analyze skin cells and inherited genetic variations as adjunct tools for melanoma management, providing a comprehensive, evidence-based foundation for clinicians regarding the management of difficult pigmented lesions. The review examined the fundamental principles behind each test, peer-reviewed literature assessing tool performance, and the utility and limitations of each assay. The published summary cites six peer-reviewed studies of the DermTech PLA. Key points from the article in reference to the DermTech PLA include:

The DermTech PLA’s high negative predictive value (“NPV”) of >99% suggest a role as a rule-out tool for melanoma, providing clinicians with additional information to reduce biopsies of benign lesions
The molecular test measures the levels of PRAME and LINC00518, two genes preferentially identified in melanoma
The non-invasive adhesive patch removes only the outermost layers of the stratum corneum and does not impact future histologic examination of the underlying epidermis
Reduction of unnecessary biopsies not only decreases patient morbidity but may reduce costs to the overall healthcare system
Physician follow-up within 6-12 months on negative results, per standard of care, should mitigate any remaining risk of missed melanoma(s)

“This review underscores the growing importance of genomic information and objective diagnostic tools in melanoma diagnosis. The revolution in cancer care brought about by genomics is beginning to take hold in dermatology, and DermTech is at the forefront of this change,” said John Dobak, M.D., Chief Executive Officer of DermTech. “Early melanoma detection is very challenging, and the DermTech PLA can reduce unnecessary pain and scarring from surgical biopsies, while improving the overall accuracy of diagnosis. As the authors note, the DermTech PLA is validated with proven clinical utility and a high sensitivity and low probability of missing melanoma.”

Surgical biopsies are the current standard method for testing suspicious lesions for melanoma, though they can cause discomfort and scarring for patients, and still carry a 17% chance of missing melanoma. Of the 4.5 million skin biopsies performed annually in the U.S. to rule out melanoma, approximately 180,000 cases of melanoma are detected. In addition, 8%-20% of pathologist-evaluated lesions are classified as ambiguous or indeterminate, demonstrating the difficulty and subjectivity in detecting melanoma based on a clinical visual assessment alone.

The DermTech PLA uses a revolutionary adhesive patch technology to collect skin cells from the surface of an entire lesion without a biopsy, leaving the lesion intact to offer dermatologists the option for additional analyses if necessary. The skin cells extracted from the patch are analyzed for genetic data associated with melanoma. The DermTech PLA is validated with proven clinical utility, and has a 91% sensitivity with less than a 1% chance of missing a melanoma (99% NPV).
👍️0
greens12 greens12 4 years ago
Don't miss Dr. John Dobak’s interview with eHealth Radio. The interview highlights the value of genomics in dermatology and Dermtech’s role in shifting the #melanoma detection landscape. https://buff.ly/2VRAsct

DMTK

DMTKW
👍️0
db7 db7 4 years ago
Glad it’s holding up and that RTW was buying on the open market recently
👍️0
greens12 greens12 4 years ago
Nice move up today, still holding all my shares and warrants, i even bought more warrants today but they sure are acting strange . Picked up some at .37 and then someone must have sold more at .32, the warrants are trading dirt cheap right now. They were just .60 a few weeks ago.

DMTK
👍️0
greens12 greens12 4 years ago
Good report, Huge revenue growth expected.

DMTK
DMTKW
👍️0
db7 db7 4 years ago
https://investors.dermtech.com/news-releases/news-release-details/dermtech-inc-reports-fourth-quarter-and-full-year-2019-financial
👍️0
Glider549 Glider549 4 years ago
https://www.insider-monitor.com/trading/cik51253.html
👍️0
db7 db7 4 years ago
open market insider purchases last 3 days-->



SEC Filing

Insider



Trade Date

Transaction

Shares

Avg. Price

Total

% Holdings

Return

Yesterday 5:10 PM
View: Rtw Investments, Lp
10% Owner Yesterday Market Purchase 23,955 $14.61 $350,088.00 < 1%
2.57M to 2.6M (6%)
Yesterday 5:10 PM
View: Rtw Investments, Lp
10% Owner 04-Mar-20 Market Purchase 4,447 $14.75 $65,593.20 < 1%
2.57M to 2.57M (7%)
Yesterday 5:10 PM
View: Rtw Investments, Lp
10% Owner 03-Mar-20 Market Purchase 13,000 $14.52 $188,713.00 < 1%
2.55M to 2.57M (5%)
👍️0
db7 db7 4 years ago
https://finance.yahoo.com/news/large-registry-study-demonstrates-clinicians-130000568.html
👍️0
greens12 greens12 4 years ago
Wall st. liked the news...Company has enough cash to last many years. Time to Ramp up Medicare sales and get the revenue flowing.

DMTK
👍️0
db7 db7 4 years ago
BEAUTIFUL day: DMTK $16, DMTKW $0.58
👍️0
db7 db7 4 years ago
not sure... why didn't they just do all common? why the preferred that 'maybe' become active 4 months from now???
👍️0
greens12 greens12 4 years ago
Key words are "or before ".... SH meeting could happen in March... "upon the approval of the Private Placement by the stockholders of DermTech, which DermTech has agreed to seek at a meeting to be held on or before June 30, 2020"

DMTK
👍️0
greens12 greens12 4 years ago
What do you mean if it rocketed ...by how much, what is the limit ? Why would it be by design ?

DMTK
👍️0
db7 db7 4 years ago
Curious setup with the B series preferred; wondering why they did that(?). Technically, if the price of DMTK rocketed prior to the June shareholder vote those might never come to fruition... maybe by design(?)
👍️0
TallTrader TallTrader 4 years ago
8K New Private placement...

Item 1.01 Entry into a Material Definitive Agreement.

On February 28, 2020, DermTech, Inc., or the Company, entered into a securities purchase agreement, or the Purchase Agreement, with certain institutional investors, or the Investors, for a private placement of the Company’s equity securities, or the Private Placement. Cowen and Company, LLC served as lead placement agent for the Private Placement, with William Blair & Company, L.L.C. acting as joint placement agent. Lake Street Capital Markets, LLC acted as co-placement agent.

The Private Placement will consist of 2,467,724 shares of common stock, or the Common Shares, at a price of $10.50 per share, 3,198.9419 shares of Series B-1 Convertible Preferred Stock, or the Series B-1 Shares, at a price of $10,500 per share, and 523.8094 shares of Series B-2 Convertible Preferred Stock, or the Series B-2 Shares, at a price of $10,500 per share, for aggregate gross proceeds of approximately $65.0 million, and net proceeds to the Company of approximately $60.0 million, after deducting estimated offering expenses payable by the Company. The closing of the Private Placement is expected to take place on or about March 4, 2020, and is subject to customary closing conditions. The Series B-1 Shares and Series B-2 Shares are collectively referred to herein as the Preferred Shares.

https://www.sec.gov/Archives/edgar/data/1651944/000119312520057797/d873792d8k.htm
👍️0
db7 db7 4 years ago
Today's presentation: http://wsw.com/webcast/svbleerink34/dmtk/
👍️0
greens12 greens12 4 years ago
Yes indeed, the Medicare revenues started this week.

DMTK
👍️0
db7 db7 4 years ago
looking 'very' ready here imo
👍️0
db7 db7 4 years ago
Peer Comparison(?) I realize they are NOT apples to apples but all diagnostic testing disruptors specifically mentioned in DMTK's latest presentation


Colorectal, Exact Sciences 'EXAS' @ $95.85 , MarketCap: ~$14,000,000,000
Lung, Guardant Health 'GH' @ $82.80 , MarketCap: ~$ 7,800,000,000
Prenatal, Natera 'NTRA' @ $36.51 , MarketCap: ~$ 2,900,000,000
Breast, Genomic Health 'GHDX' @ $63.44*, MarketCap: ~$ 2,400,000,000
Thyroid, Veracyte 'VCYT' @ $26.54 , MarketCap: ~$ 1,300,000,000
Heart, CareDx 'CDNA' @ $25.07 , MarketCap: ~$ 1,100,000,000
Skin, DermTech 'DMTK' @ $13.55 , MarketCap: ~$ 148,000,000

* GHDX quote prior to becoming part of EXAS


IMO, the future is bright for our still under the radar DMTK...










Please verify my dd..etc..etc....







👍️0
db7 db7 4 years ago
unless you're heard otherwise, I highly doubt they will relist them on the Nasdaq; no benefit to them at all. If anything, probably extra hoops to jump through and associated costs...

Warrants will react appropriately no matter the venue, especially once in the money (although of course we lose some premium and institutional buyers being non Nasdaq-listed)
















👍️0
greens12 greens12 4 years ago
Good to see the CEO getting the word out to investors. Have you heard any news on Warrants getting listed back on Nasdaq ?

DMTK
👍️0
db7 db7 4 years ago
DermTech to Present at Upcoming Investor Conferences

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that John Dobak, M.D., Chief Executive Officer of the Company, is scheduled to present at the following upcoming investor conferences:
• The 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 2:30 p.m. Eastern Time at the Lotte New York Palace hotel in New York.
• Cowen’s 40th Annual Health Care Conference on Monday, March 2, 2020 at 11:20 a.m. Eastern Time at the Boston Marriott Copley Place hotel in Boston.

About DermTech:

DermTech is a leader in a new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to the performance, patient benefits and cost-effectiveness of DermTech’s products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) by the company, and (y) other documents filed or to be filed with the SEC by the company. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.



View source version on businesswire.com: https://www.businesswire.com/news/home/20200211006081/en/

Company Contact:
Sarah Dion
VP Marketing
sdion@dermtech.com
(858) 450-4222

Investors:
Westwicke, an ICR company
Caroline Corner, PhD
caroline.corner@westwicke.com
(415) 202-5678

👍️0
db7 db7 4 years ago
really waiting/hoping for a parabolic move myself... hope it pans out

👍️0
greens12 greens12 4 years ago
Strong day for DMTK, commons and especially the warrants going crazy on heavy Volume . Should break out to 20.00 soon.

DMTK
👍️0
greens12 greens12 4 years ago
53 new sales reps coming should get the ball rolling. What exactly is Adoption through optimized clinician messaging ?

DMTK
👍️0
db7 db7 4 years ago
New Presentation: https://www.sec.gov/Archives/edgar/data/1651944/000156459020002551/dmtk-ex991_6.htm
👍️0
greens12 greens12 4 years ago
When is Earnings report ?

DMTK
👍️0

Your Recent History

Delayed Upgrade Clock